Actinium Pharmaceuticals, Inc. (NYSE:ATNM - Free Report) - Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for Actinium Pharmaceuticals in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($1.13) per share for the year. HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals' current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals' FY2028 earnings at ($1.24) EPS.
Actinium Pharmaceuticals Trading Down 9.0 %
NYSE:ATNM traded down $0.15 on Friday, hitting $1.47. 451,963 shares of the stock were exchanged, compared to its average volume of 499,398. The stock has a fifty day moving average of $1.26 and a 200-day moving average of $1.44. The stock has a market cap of $45.70 million, a PE ratio of -1.05 and a beta of 0.10. Actinium Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $10.24.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC increased its position in shares of Actinium Pharmaceuticals by 25.4% in the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company's stock worth $231,000 after acquiring an additional 37,159 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Actinium Pharmaceuticals by 49.5% in the 4th quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company's stock valued at $187,000 after purchasing an additional 49,214 shares in the last quarter. Deutsche Bank AG raised its position in Actinium Pharmaceuticals by 413.6% in the fourth quarter. Deutsche Bank AG now owns 123,134 shares of the company's stock valued at $155,000 after purchasing an additional 99,158 shares during the period. Bank of America Corp DE lifted its stake in shares of Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company's stock worth $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company's stock worth $317,000 after buying an additional 11,812 shares during the period. Hedge funds and other institutional investors own 27.50% of the company's stock.
About Actinium Pharmaceuticals
(
Get Free Report)
Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
Further Reading
Before you consider Actinium Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actinium Pharmaceuticals wasn't on the list.
While Actinium Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
